Xiaomei Ma, PhD
Interim Department Chair and Professor of Epidemiology (Chronic Diseases)DownloadHi-Res Photo
Cards
Additional Titles
Co-Leader, Cancer Prevention and Control
Contact Info
Chronic Disease Epidemiology
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
About
Copy Link
Titles
Interim Department Chair and Professor of Epidemiology (Chronic Diseases)
Co-Leader, Cancer Prevention and Control
Biography
Dr. Ma is Professor of Epidemiology at the Yale School of Public Health, and Co-Leader of the Cancer Prevention and Control Research Program at the Yale Comprehensive Cancer Center, Yale School of Medicine. She studies the etiology and health outcomes of different types of cancer, with a focus on pediatric cancer and malignancies of the hematopoietic system (e.g., leukemia, lymphoma, myelodysplastic syndromes, and myeloproliferative neoplasms). Her research has addressed the impact of immunological factors, chemical exposures, and genetic characteristics on the risk of cancer. In addition, she has assessed the patterns of care and cost implications of cancer screening and treatment in older adults.
Last Updated on May 09, 2025.
Appointments
Chronic Disease Epidemiology
Interim ChairDualChronic Disease Epidemiology
ProfessorPrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Chronic Disease Epidemiology
- Climate Change and Health
- COPPER Center
- K12 Calabresi Immuno-Oncology Training Program (IOTP)
- Yale Cancer Center
- Yale School of Public Health
- Yale Ventures
Education & Training
- PhD
- University of California at Berkeley (2001)
Research
Copy Link
Overview
Medical Research Interests
Chronic Disease; Epidemiology; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms
Public Health Interests
Chronic Diseases; Cancer; Aging; Health Policy; Maternal & Child Health
ORCID
0000-0001-9472-8032
Research at a Glance
Yale Co-Authors
Frequent collaborators of Xiaomei Ma's published research.
Publications Timeline
A big-picture view of Xiaomei Ma's research output by year.
Research Interests
Research topics Xiaomei Ma is interested in exploring.
Rong Wang, PhD
Amer Zeidan, MBBS
Nikolai Podoltsev, MD, PhD
Scott Huntington, MD, MPH, MSc
Cary P Gross, MD
Michael S. Leapman, MD, MHS
290Publications
9,374Citations
Myelodysplastic Syndromes
Neoplasms
Leukemia
Myeloproliferative Disorders
Chronic Disease
Lymphoma
Publications
2025
Association between prostate specific membrane antigen imaging and initial treatment for prostate cancer among commercial insurance beneficiaries.
Leapman M, Rothen J, Long J, Kim I, Mitchell A, Dinan M, Gross C, Ma X. Association between prostate specific membrane antigen imaging and initial treatment for prostate cancer among commercial insurance beneficiaries. JCO Oncology Practice 2025, 21: 577-577. DOI: 10.1200/op.2025.21.10_suppl.577.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyPSMA-PETProstate cancerBone scanInitial treatmentLocal therapyProstate specific membrane antigen positron emission tomographyIncident diagnosis of prostate cancerPSMA imagingAndrogen deprivation therapy useLandscape of prostate cancerDiagnosis of prostate cancerDiagnostic landscapePSMA PET imagingPSMA-PET scansImaging modalitiesMetastatic prostate cancerIncident diagnosisRetrospective cohort studyPrimary study outcomeBone scintigraphy imagesPositron emission tomographyNational Drug CodesCommercial insurance beneficiariesDeprivation therapyDistinct metabolic and genetic alterations in tumors from early-onset versus late-onset colorectal cancer
Janak A, Jain A, Garcia-Milian R, Aladelokun O, Ma X, Paty P, Khan S, Johnson C. Distinct metabolic and genetic alterations in tumors from early-onset versus late-onset colorectal cancer. Free Radical Biology And Medicine 2025, 240: 773-782. PMID: 40865779, DOI: 10.1016/j.freeradbiomed.2025.08.052.Peer-Reviewed Original ResearchAltmetricConceptsLate-onset colorectal cancerEO-CRCColorectal cancerTumor metabolomeMass spectrometry-based untargeted metabolomicsTumor tissuesCatecholamine metabolismGroup of CRC patientsMetabolite set enrichment analysisPatient-matched normal tissuesTumor-specific differencesEarly-onset colorectal cancerMetabolite of dopaminePD-L1Untargeted metabolomicsCRC patientsOxidative stress-related genesHomovanillic acidGenetic alterationsEarly-onsetTumorTherapeutic strategiesGene expression validationNormal tissuesEGFR SignalingSecond malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib
Wang R, Stempel J, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Bewersdorf J, Mendez L, Ma X, Podoltsev N. Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. Blood Neoplasia 2025, 2: 100159. PMID: 41216598, PMCID: PMC12597058, DOI: 10.1016/j.bneo.2025.100159.Peer-Reviewed Original ResearchAltmetricConceptsSecond malignanciesMyeloproliferative neoplasmsOlder patientsEssential thrombocythemiaPolycythemia veraPhiladelphia chromosome-negative myeloproliferative neoplasmsDevelopment of second malignanciesRisk of non-melanoma skin cancerEnd Results Medicare-linked databaseNon-melanoma skin cancerMedian Follow-UpMedicare-linked databaseTherapy-related effectsRetrospective cohort analysisRisk of SMHazards regression modelsProportion of daysRuxolitinib exposureMedian ageFollow-upRuxolitinibCohort analysisSkin cancerPatientsMyelofibrosisArea-Level Social Deprivation and Use of Prostate MRI Before Prostate Biopsy Among Commercial Insurance Beneficiaries
Smani S, Wang R, Zhou X, Sprenkle P, Kim I, Dinan M, Gross C, Ma X, Leapman M. Area-Level Social Deprivation and Use of Prostate MRI Before Prostate Biopsy Among Commercial Insurance Beneficiaries. Urology 2025, 205: 145-151. PMID: 40759400, DOI: 10.1016/j.urology.2025.07.070.Peer-Reviewed Original ResearchAltmetricConceptsPre-biopsy magnetic resonance imagingProstate magnetic resonance imagingMagnetic resonance imagingMagnetic resonance imaging useProstate biopsySocial deprivation indexArea-level measuresDynamic cohort studyMRI useMeasure of area-level deprivationSocioeconomic statusArea-level social deprivationArea-level measures of socioeconomic statusMeasures of socioeconomic statusStrata of socioeconomic statusArea-level deprivationCommercial insurance beneficiariesComposite measureBiopsyProstateNon-metropolitan areasDeprivation indexRural/urban statusResonance imagingSociodemographic factorsCalcineurin inhibitor and eltrombopag combination for acquired aplastic anemia: results from a large national database
Stempel J, Wang R, Lee A, Zeidan A, Ma X, Podoltsev N. Calcineurin inhibitor and eltrombopag combination for acquired aplastic anemia: results from a large national database. Therapeutic Advances In Hematology 2025, 16: 20406207251394775. PMID: 41333634, PMCID: PMC12665816, DOI: 10.1177/20406207251394775.Peer-Reviewed Original ResearchConceptsAcquired Aplastic AnemiaCalcineurin inhibitorsTransfusion requirementsTransfusion burdenDouble therapySevere AATriple therapyAplastic anemiaCombination therapyAllogeneic hematopoietic stem cell transplantationEquine anti-thymocyte globulinEffects of calcineurin inhibitorsRare bone marrow failure syndromeHematopoietic stem cell transplantationBone marrow failure syndromesFirst-line treatment optionAnti-thymocyte globulinStem cell transplantationMarrow failure syndromesTreatment-related complicationsImmune-mediated destructionRisk of bleedingRetrospective cohort studyAdherence to treatmentTransfusion-independentAssociation Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis
Theprungsirikul P, Wang R, Ahmad I, Neparidze N, Ma X, Chang S, Wang S. Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis. Clinical Lymphoma Myeloma & Leukemia 2025, 25: e942-e949. PMID: 40670211, DOI: 10.1016/j.clml.2025.06.016.Peer-Reviewed Original ResearchConceptsSmoldering Multiple MyelomaSmoldering multiple myeloma patientsMultiple myelomaPatient demographicsProgression to multiple myelomaSymptomatic multiple myelomaDevelopment of hypercalcemiaCox proportional hazards modelsRisk stratification modelConfidence intervalsNon-cancer controlsEstimate hazard ratiosProportional hazards modelNon-cancer patientsSymptomatic MMRandom sample of Medicare beneficiariesSMM patientsRenal failureAnalyzed SurveillanceSEER-MedicareNatural history modelHazard ratioBone diseasePatientsSample of Medicare beneficiariesPerinatal Exposures to Ambient Fine Particulate Matter and Outdoor Artificial Light at Night and Risk of Pediatric Papillary Thyroid Cancer
Deziel N, Wang R, Warren J, Dinauer C, Ogilvie J, Clark C, Zhong C, Wiemels J, Morimoto L, Metayer C, Ma X. Perinatal Exposures to Ambient Fine Particulate Matter and Outdoor Artificial Light at Night and Risk of Pediatric Papillary Thyroid Cancer. Environmental Health Perspectives 2025, 133: 057026. PMID: 40209106, PMCID: PMC12121722, DOI: 10.1289/ehp14849.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdolescentAir PollutantsCaliforniaCarcinoma, PapillaryCase-Control StudiesChildChild, PreschoolEnvironmental ExposureFemaleHumansInfantInfant, NewbornLightingMaleParticulate MatterPregnancyPrenatal Exposure Delayed EffectsRisk FactorsThyroid Cancer, PapillaryThyroid NeoplasmsYoung AdultConceptsThyroid cancer riskOutdoor artificial lightAmbient fine particulate matterCancer riskOdds ratioAge groupsConfidence intervalsExposure to ambient fine particulate matterIndividual-level exposuresAssociated with thyroid cancerPediatric thyroid cancer incidenceControls frequency-matchedPapillary thyroid cancer riskThyroid cancer incidenceFine particulate matterCalifornia birth cohortOutdoor air pollutionAerodynamic diameter <Case-control studyHypothesized risk factorsStatistically significant associationCancer incidenceThyroid cancerExposure tertilesFrequency-matchedInitial management of patients with acquired aplastic anemia in the United States: results from a large national claims database
Stempel J, Wang R, Lee A, Zeidan A, Ma X, Podoltsev N. Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database. Annals Of Hematology 2025, 104: 2507-2515. PMID: 40102305, PMCID: PMC12052795, DOI: 10.1007/s00277-025-06307-z.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsHematopoietic stem cell transplantationAcquired Aplastic AnemiaCalcineurin inhibitorsParoxysmal nocturnal hemoglobinuriaTransfusion-DependentTriple therapyAA patientsAplastic anemiaAllogeneic hematopoietic stem cell transplantationTreated with calcineurin inhibitorsTreated with antithymocyte globulinFlow cytometryInitial management of patientsSevere AA patientsStem cell transplantationBone marrow failureImmune-mediated disordersTreatment initiation delayRetrospective cohort studyManagement of patientsDiagnosis to treatmentNational claims databaseAntithymocyte globulinSibling donorMarrow failurePerinatal exposure to ambient fine particle air pollution and risk of childhood ewing sarcoma in a population-based case-control study in California (1988–2015)
Clark C, Wang R, Wiemels J, Metayer C, Deziel N, Ma X. Perinatal exposure to ambient fine particle air pollution and risk of childhood ewing sarcoma in a population-based case-control study in California (1988–2015). Environmental Health 2025, 24: 6. PMID: 40055781, PMCID: PMC11887085, DOI: 10.1186/s12940-025-01159-6.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsHispanic childrenSarcoma riskControls frequency-matched to casesFrequency-matched to casesBirth yearPopulation-based case-control studyOdds ratioPM2.5 exposureConfidence intervalsAir pollution exposureCalifornia birth cohortNon-Hispanic childrenAmbient PM2.5 exposureFine particle air pollutionCase-control studyAmbient fine particulate matterHigher PM2.5 levelsMaternal residenceCancer riskMaternal educationPotential disparitiesBirth cohortHispanic ethnicityElevated oddsLinkage studiesPrenatal exposure to per- and polyfluoroalkyl substances (PFAS) from contaminated water and risk of childhood cancer in California, 2000–2015
Binczewski N, Morimoto L, Wiemels J, Ma X, Metayer C, Vieira V. Prenatal exposure to per- and polyfluoroalkyl substances (PFAS) from contaminated water and risk of childhood cancer in California, 2000–2015. Environmental Epidemiology 2025, 9: e365. PMID: 39802752, PMCID: PMC11723701, DOI: 10.1097/ee9.0000000000000365.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAdjusted odds ratiosPolyfluoroalkyl substancesPerfluorooctanesulfonic acidPerfluorooctanoic acidWilms tumorEmbryonal tumorsChildhood cancerSerum concentrationsIncreased risk of Wilms tumorRisk of Wilms tumorNon-Hodgkin's lymphomaRisk of childhood cancerMaternal serum concentrationsAcute myeloid leukemiaLevels of PFASConcentrations of perfluorooctanesulfonic acidConfidence intervalsContaminant Monitoring RuleContaminated drinking waterExposure to per-Myeloid leukemiaMexico-born mothersHealthy controlsIncreased riskContaminated water
News
Copy Link
News
- October 28, 2025Source: Yale News
Study Reveals Demographic Disparities in Uptake of Colorectal Cancer Screenings
- September 10, 2025Source: STAT
Risk of dying from chronic disease in the U.S. declined, but there are caveats, study says
- June 03, 2025Source: Yale News
Insights & Outcomes: Star Music, Kavli Kudos, and Summertime Heart Risks
- May 14, 2025
Faculty Research Awards Showcase YSPH Strengths in Science
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Office Fax Number
Mailing Address
Chronic Disease Epidemiology
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
Locations
60 College Street
Academic Office
Ste 406
New Haven, CT 06510